ImmunoCellular Therapeutics is a clinical-stage company engaged in the development of immune-based therapies to treat brain and other cancers. The company is conducting a Phase 2 trial of its lead product candidate, ICT-107, which is a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. The company’s pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133; and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. For more information, visit the company’s Web site: http://www.imuc.com
Let us hear your thoughts below: